KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) EPS (Weighted Average and Diluted) (2020 - 2025)

Bionano Genomics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$1.58 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 95.17% year-over-year to -$1.58; the TTM value through Sep 2025 reached -$12.77, up 97.29%, while the annual FY2024 figure was -$88.13, 78.43% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$1.58 at Bionano Genomics, up from -$2.09 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q1 2021 and bottomed at -$402.75 in Q4 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.23 (2023), against an average of -$25.99.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 30880.77% in 2023 before it skyrocketed 98.03% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.08 in 2021, then tumbled by 1525.0% to -$1.3 in 2022, then tumbled by 30880.77% to -$402.75 in 2023, then surged by 98.03% to -$7.95 in 2024, then surged by 80.13% to -$1.58 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's EPS (Weighted Average and Diluted) are -$1.58 (Q3 2025), -$2.09 (Q2 2025), and -$1.15 (Q1 2025).